Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Int J Mol Sci ; 21(11)2020 May 27.
Article in English | MEDLINE | ID: mdl-32471263

ABSTRACT

Parkinson's disease (PD) is a long-term degenerative disease of the central nervous system (CNS) that primarily affects the motor system. So far there is no effective treatment for PD, only some drugs, surgery, and comprehensive treatment can alleviate the symptoms of PD. Stem cells derived from human exfoliated deciduous teeth (SHED), mesenchymal stem cells derived from dental pulp, may have promising potential in regenerative medicine. In this study, we examine the therapeutic effect of SHED-derived conditioned medium (SHED-CM) in a rotenone-induced PD rat model. Intravenous administration of SHED-CM generated by standardized procedures significantly improved the PD symptoms accompanied with increased tyrosine hydroxylase amounts in the striatum, and decreased α-synuclein levels in both the nigra and striatum, from rotenone-treated rats. In addition, this SHED-CM treatment decreased both Iba-1 and CD4 levels in these brain areas. Gene ontology analysis indicated that the biological process of genes affected by SHED-CM was primarily implicated in neurodevelopment and nerve regeneration. The major constituents of SHED-CM included insulin-like growth factor binding protein-6 (IGFBP-6), tissue inhibitor of metalloproteinase (TIMP)-2, TIMP-1, and transforming growth factor 1 (TGF-1). RNA-sequencing (RNA-seq) and Ingenuity Pathway Analysis (IPA) revealed that these factors may ameliorate PD symptoms through modulating the cholinergic synapses, calcium signaling pathways, serotoninergic synapses, and axon guidance. In conclusion, our data indicate that SHED-CM contains active constituents that may have promising efficacy to alleviate PD.


Subject(s)
Culture Media, Conditioned/pharmacology , Mesenchymal Stem Cells/metabolism , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Tooth, Deciduous/cytology , Animals , Cells, Cultured , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Culture Media, Conditioned/chemistry , Female , Humans , Injections, Intravenous , Insulin-Like Growth Factor Binding Protein 6/analysis , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Rats , Rats, Inbred Lew , Tissue Inhibitor of Metalloproteinases/analysis , Transforming Growth Factor beta/analysis , Tyrosine 3-Monooxygenase/metabolism , alpha-Synuclein/metabolism
2.
Am J Physiol Regul Integr Comp Physiol ; 296(5): R1348-57, 2009 May.
Article in English | MEDLINE | ID: mdl-19279291

ABSTRACT

Insulin-like growth factor binding proteins (IGFBPs) are high-affinity binding partners for IGFs and play important roles in modulating IGF activities. In this study, we have identified and characterized two functional IGFBP-6 genes in zebrafish. Structural, phylogenetic, and comparative genomic analyses indicate that they are co-orthologs of the human IGFBP-6 gene. To gain insight into how the duplicated genes may have evolved through partitioning of ancestral functions, gene expression and functional studies were carried out. In adult fish, IGFBP-6a mRNA was most abundantly expressed in the muscle. The levels of IGFBP-6a mRNA in nonmuscle tissues were very low or barely detectable. In comparison, the levels of IGFBP-6b mRNA were high in the brain, heart, and muscle, but very low or undetectable in other adult tissues. During embryogenesis, the IGFBP-6a mRNA levels were relatively low. The IGFBP-6b mRNA levels were low during the initial 48 h. They became significantly higher at 72 and 96 h postfertilization. Overexpression of zebrafish IGFBP-6a and IGFBP-6b caused a similar degree of reduction in body size and developmental rate. No notable effects were observed on cell fate or patterning in these transgenic fish. These data suggest that the duplicated igfbp-6 genes encode two functionally similar proteins, but they have evolved distinct spatial and temporal expression patterns. These findings are consistent with the notion of an additional gene duplication event in teleost fish and have provided novel insight into the structural and functional evolution of the IGFBP gene family.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/metabolism , Zebrafish/genetics , Zebrafish/metabolism , Amino Acid Sequence , Animals , Brain/embryology , Brain/metabolism , Cattle , Chickens , Chromosome Mapping , Embryonic Development/genetics , Embryonic Development/physiology , Heart/embryology , Humans , Insulin-Like Growth Factor Binding Protein 6/analysis , Mice , Molecular Sequence Data , Muscles/embryology , Muscles/metabolism , Myocardium/metabolism , Phylogeny , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Salmon , Trout , Xenopus , Zebrafish/embryology
3.
Reproduction ; 135(1): 63-75, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18159084

ABSTRACT

Negative energy balance (NEB) during early lactation in dairy cows leads to an altered metabolic state that has major effects on the production of IGF family members. Low IGF-I concentrations are associated with poor fertility and therefore we aimed to determine whether NEB exerts a direct effect on IGF expression in the postpartum oviduct. Multiparous Holstein cows were allocated to two treatments (each n=6) designed using differential feeding and milking regimes to produce either mild NEB (MNEB) or severe NEB (SNEB). Animals were slaughtered in week 2 of lactation when divergent metabolic profiles were evident. Oviducts were collected for RNA analysis by real-time RT-PCR and in situ hybridisation. Quantitative measures in oviduct gene expression were obtained for all members of the IGF family (IGF-I/II, IGF-binding proteins (IGFBP) 1-6 and receptors for IGF types 1 and 2), insulin A/B, GH, glucocorticoid and oestrogen alpha/beta. Expression of IGFBP-2 and IGFBP-6 (both of which have a high affinity for IGF-II) was decreased in SNEB relative to MNEB (P<0.05). No other gene was altered by NEB, but IGF-II, IGFBP-3, IGFBP-5 and IGFBP-6 all showed differential expression in different regions of the oviduct. These results indicate that, in addition to low circulating IGF-I after calving, NEB may also influence IGF availability in the oviduct indirectly through changes in specific IGFBP expression. It is possible that the predicted increased signalling by IGF-II may perturb embryo development, contributing to the high rates of embryonic mortality in dairy cows.


Subject(s)
Cattle/metabolism , Dairying , Energy Metabolism , Fallopian Tubes/metabolism , Insulin-Like Growth Factor Binding Proteins/metabolism , Lactation/metabolism , Animals , Autoradiography , Fallopian Tubes/chemistry , Female , Fetal Death , Gene Expression , In Situ Hybridization/methods , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/metabolism , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/analysis , Insulin-Like Growth Factor II/genetics , Insulin-Like Growth Factor II/metabolism , Pregnancy , RNA, Messenger/analysis , Receptors, Somatotropin/genetics , Receptors, Somatotropin/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Signal Transduction/physiology
4.
Endocrinology ; 149(3): 1214-26, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18039785

ABSTRACT

IGF binding protein (IGFBP)-6 is a member of the IGFBP family that regulates the actions of IGFs. Although IGFBPs exert their functions extracellularly in an autocrine/paracrine manner, several members of the family, such as IGFBP-3 and -5, possess nuclear localization signals (NLS). To date, no NLS has been described for IGFBP-6, an IGFBP that binds preferentially to IGF-II. We report here that both exogenous and endogenous IGFBP-6 could be imported into the nuclei of rhabdomyosarcoma and HEK-293 cells. Nuclear import of IGFBP-6 was mediated by a NLS sequence that bears limited homology to those found in IGFBP-3 and -5. IGFBP-6 nuclear translocation was an active process that required importins. A peptide corresponding to the IGFBP-6 NLS bound preferentially to importin-alpha. A comprehensive peptide array study revealed that, in addition to positively charged residues such as Arg and Lys, amino acids, notably Gly and Pro, within the NLS, played an important part in binding to importins. Overexpression of wild-type IGFBP-6 increased apoptosis, and the addition of IGF-II did not negate this effect. Only the deletion of the NLS segment abolished the apoptosis effect. Taken together, these results suggest that IGFBP-6 is translocated to the nucleus with functional consequences and that different members of the IGFBP family have specific nuclear import mechanisms.


Subject(s)
Cell Nucleus/metabolism , Insulin-Like Growth Factor Binding Protein 6/metabolism , Nuclear Localization Signals/metabolism , Active Transport, Cell Nucleus/physiology , Adenosine Triphosphate/metabolism , Amino Acid Sequence , Cell Line , Cell Nucleus/pathology , Humans , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor Binding Protein 5/metabolism , Insulin-Like Growth Factor Binding Protein 6/analysis , Kidney/embryology , Kidney/metabolism , Kidney/pathology , Molecular Sequence Data , Nuclear Localization Signals/analysis , Rhabdomyosarcoma/metabolism , Rhabdomyosarcoma/pathology , Tumor Cells, Cultured , alpha Karyopherins/metabolism , beta Karyopherins/metabolism
5.
Eur J Oral Sci ; 114(4): 318-27, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16911103

ABSTRACT

There is evidence that growth factors, such as the insulin-like growth factors (IGFs), are involved in biological and pathological processes in oro-dento-facial tissues. To investigate their roles in tooth movement, root resorption, and repair, the occurrence of components of the IGF system, including the ligands IGF-I and -II, the IGF receptor 1 (IGF1R) and six IGF-binding proteins (IGFBP-1 to -6), was investigated by immunohistochemistry on sections from rat maxillae where the first molar had been moved mesially by means of an orthodontic appliance for 9 d to induce root resorption. After force deactivation on day 0, early repair was studied after a further 5, 7, 10, 12, 14, and 17 d. The immunostaining pattern in the periodontal ligament, cementum, and bone of control animals showed similarities known from studies in human teeth. Increased immunostaining for nearly all components in pressure sides and resorption lacunae indicated an involvement in resorption processes and clastic activities. During early stages of repair, the occurrence of several components (e.g. IGF-II, IGFBP-5 or -6) within lacunae and in cementoblasts showed an involvement in the resorption-repair sequence, which is considered to be a coupling process as known from bone.


Subject(s)
Periodontium/physiopathology , Root Resorption/physiopathology , Somatomedins/physiology , Alveolar Process/pathology , Alveolar Process/physiopathology , Animals , Dental Cementum/pathology , Dental Cementum/physiopathology , Immunohistochemistry , Insulin-Like Growth Factor Binding Protein 1/analysis , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor II/analysis , Male , Periodontal Ligament/pathology , Periodontal Ligament/physiopathology , Periodontium/pathology , Rats , Rats, Wistar , Receptor, IGF Type 1/analysis , Root Resorption/pathology , Somatomedins/analysis , Time Factors , Tooth Movement Techniques , Wound Healing/physiology
6.
J Endocrinol ; 186(1): 165-78, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16002546

ABSTRACT

Elucidating how mitogens facilitate epithelial/stromal interactions is critical given that mitogens regulate mammary gland development and function. IGF-I is a potent mammary cell mitogen that is locally produced in the mammary gland. Since IGF-binding proteins (IGFBPs) regulate IGF-I bioavailability, we characterized the cell-type-specific production of IGFBP in primary bovine mammary epithelial (BME) and fibroblast (BMF) cells. Cells were treated with IGF-I and mRNA levels were analyzed via quantitative real-time (qRT)-PCR and Northern blot analysis. Media conditioned by cells treated with IGF-I for 48 h were analyzed via ligand blotting with 125I-labeled IGF-I and -II and immunoblotting with specific IGFBP antibodies. A reciprocal regulation of IGFBP-3 and -5 by IGF-I was observed between the two cell types. IGF-I induced large dose-dependent increases in IGFBP-3 mRNA and protein levels in BME cells, while IGFBP-5 protein was barely detectable and mRNA levels were detectable only by qRT-PCR. In BMFs, IGF-I induced large increases in IGFBP-5 mRNA and protein while IGFBP-3 mRNA was only slightly increased by IGF-I treatment and the protein was difficult to detect. IGFBP-6 mRNA was detected by Northern blot analysis in both cell types but was not regulated by IGF-I. In BME cells, IGFBP-6 protein levels were readily detectable under basal conditions and were increased by IGF-I. Interestingly, IGFBP-6 protein could not be detected in media conditioned by BMFs. IGFBP-4 mRNA was readily seen by Northern blot analysis in BMFs, however qRT-PCR was required to detect IGFBP-4 mRNA in BME cells. IGF-I increased IGFBP-4 mRNA levels by 2-fold in both cell types. IGFBP-4 protein was only detectable in media conditioned by BME cells when stimulated by IGF-I. In contrast, IGFBP-4 was present in media conditioned by untreated BMFs but was not consistently increased by IGF-I treatment. This was explained by the finding that IGF-I stimulated proteolysis of IGFBP-4, as evidenced by the appearance of two immuno-responsive fragments of 18 and 14 kDa. This proteolysis was specific to IGFBP-4, and was not observed in BME cells. We confirmed the protease to be pregnancy-associated plasma protein A (PAPP-A) by immunoblotting with an antibody against human PAPP-A/proMBP (pro form of eosinophil major basic protein) complex. In vitro immuno-neutralization experiments showed that blocking PAPP-A prevented the ability of IGF-I to stimulate IGFBP-4 proteolysis. IGFBP-2 mRNA and protein levels were observed under basal conditions in both cell types, with no significant regulation by IGF-I. The analysis of cell-type-specific regulation of the IGF system in both primary mammary epithelial cells and stromal cells will assist in the characterization of the mechanisms behind the role of the IGF system in normal mammary physiology and ultimately breast cancer.


Subject(s)
Gene Expression Regulation , Insulin-Like Growth Factor Binding Proteins/metabolism , Insulin-Like Growth Factor I/pharmacology , Mammary Glands, Animal/metabolism , Animals , Blotting, Northern/methods , Blotting, Western/methods , Cattle , Cells, Cultured , Culture Media, Conditioned , Dose-Response Relationship, Drug , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 5/metabolism , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/metabolism , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor I/metabolism , Mammary Glands, Animal/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
7.
Mol Cell Proteomics ; 4(9): 1273-83, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15958393

ABSTRACT

Fibroblasts are the most ubiquitous cell types within our body. They produce various factors to maintain the texture and structure of a particular organ or tissue. To identify protein factors secreted by fibroblasts and alteration of these protein factors upon oxidative stress, HCA3 human skin diploid fibroblasts were exposed to a sublethal dose of H2O2, which induces a prematurely senescent phenotype. Conditioned media from prematurely senescent cells versus control cells were analyzed for proteins using an LC-MS/MS-based proteomic technique. Collagen alpha1(VI), collagen alpha2(I), fibronectin, lumican, and matrix metalloproteinase 2 were among the proteins consistently detected from control and H2O2-treated cells. Insulin-like growth factor-binding protein-6 (IGFBP-6) consistently showed up in the conditioned medium of H2O2-treated cells but not from untreated cells. Increased IGFBP-6 production due to H2O2 treatment was confirmed by RT-PCR and Western blot analyses. While H2O2 induced a dose-dependent elevation of IGFBP-6 mRNA, Western blot analyses detected elevated levels of IGFBP-6 protein in the conditioned medium of H2O2-treated cells. In comparison, fibronectin or matrix metalloproteinase 2 did not show changes at the mRNA level in cell lysates or at the protein level in the conditioned medium by H2O2 treatment. Using several types of toxins at sublethal doses, including cis-platin, hydroxyurea, colchicine, L-mimosine, rhodamine, dithiothreitol, or N-ethylmaleimide, we found that these agents induced increases of IGFBP-6 at mRNA and protein levels. An increased level of IGFBP-6 protein was detected in the plasma of aging mice and of young mice treated with doxorubicin. These data suggest that IGFBP-6 may serve as a sensitive biomarker of cell degeneration or injury in vitro and in vivo.


Subject(s)
Diploidy , Fibroblasts/metabolism , Hydrogen Peroxide/pharmacology , Insulin-Like Growth Factor Binding Protein 6/metabolism , Oxidants/pharmacology , Oxidative Stress/drug effects , Proteomics , Blotting, Western , Cell Extracts , Chromatography, Liquid , Culture Media, Conditioned/chemistry , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Humans , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/genetics , Mass Spectrometry , Reverse Transcriptase Polymerase Chain Reaction
8.
Reproduction ; 129(3): 337-47, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15749960

ABSTRACT

Postnatal development of the ovine uterus primarily involves uterine gland morphogenesis or adenogenesis. Adenogenesis involves the budding differentiation of the glandular epithelium (GE) from the luminal epithelium (LE) and then GE proliferation and coiling/branching morphogenetic development within the stroma between birth (postnatal day or PND 0) and PND 56. Insulin-like growth factor (IGF)-I and IGF-II mRNAs were previously found to be expressed only in the endometrial stroma, whereas the IGF receptor (IGF-1R) mRNA was most abundant in epithelia and in stroma, suggesting that an intrinsic IGF system regulates postnatal development of the uterus. Given that the biological activities of IGFs are modulated by a family of six IGF binding proteins (IGFBPs) and specific proteases, the objective was to determine the effects of age and estrogen disruption on expression of IGFs, IGFBPs and pregnancy-associated plasma protein A (PAPP-A or IGFBP-4 protease) in the ovine uterus. In Study One, circulating levels of IGF-I and IGF-II in the serum of neonatal ewes did not change between PND 0 and PND 56. Levels of immunoreactive IGF-I, IGF-II and IGF-1R protein were most abundant on the apical surface of the endometrial LE and GE. RT-PCR analyses detected expression of IGFBPs (3, 4, 5 and 6) as well as PAPP-A mRNAs in the uterus, but not IGFBP-1 and IGFBP-2 mRNAs. IGFBP-3 and IGFBP-4 mRNAs were expressed specifically in the endometrial stroma and myometrium and increased after birth. PAPP-A mRNA was expressed specifically in the endometrial stroma and increased after birth. In Study Two, ewes were treated from birth with estradiol-17beta valerate (EV), which reduces uterine growth and inhibits endometrial adenogenesis. On PNDs 14 and 56, IGFBP-3 mRNA was decreased in the uterus of EV-treated ewes, but IGF-1R and IGFBP-4 mRNAs were not affected. PAPP-A mRNA was increased by EV treatment on PND 14, but decreased on PND 56. These results support the hypothesis that an intrinsic IGF system in the uterus regulates epithelial-stromal interactions important for postnatal uterine growth and endometrial gland morphogenesis in the sheep.


Subject(s)
Animals, Newborn/physiology , Estradiol/analogs & derivatives , Sheep/metabolism , Somatomedins/metabolism , Uterus/metabolism , Animals , Epithelium/drug effects , Epithelium/growth & development , Epithelium/metabolism , Estradiol/pharmacology , Estrogens, Conjugated (USP)/pharmacology , Female , Insulin-Like Growth Factor Binding Protein 1/analysis , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/analysis , Insulin-Like Growth Factor II/metabolism , Morphogenesis/physiology , Pregnancy-Associated Plasma Protein-A/analysis , Pregnancy-Associated Plasma Protein-A/genetics , Pregnancy-Associated Plasma Protein-A/metabolism , RNA, Messenger/analysis , Receptor, IGF Type 1/analysis , Receptor, IGF Type 1/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Somatomedins/analysis , Uterus/drug effects , Uterus/growth & development
10.
Eur J Oral Sci ; 111(1): 26-33, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12558805

ABSTRACT

So-called epithelial rests of Malassez are derived from the Hertwig's root sheath and are located in the periodontal ligament, with still unknown functions. Different pathological conditions may lead to proliferation of these otherwise non-proliferative cell clusters. The insulin-like growth factor (IGF) system is an important growth factor system controlling proliferation and differentiation. In our study on Malassez cells from extracted human deciduous teeth, we investigated their structure by means of light and electron microscopy. Although they appeared as cellular clusters with a uniform epithelial phenotype, immunohistochemical analyses of components of the IGF system revealed an unique pattern: weak immunoreactivity could be seen for IGF-II while among all IGF binding proteins (IGFBPs) only IGFBP-6 and weakly IGFBP-4 were detectable in epithelial cells of Malassez. Since IGFBP-6 has a very high affinity for IGF-II and can inhibit its functions, we discuss that, in the normal periodontal ligament, autocrine IGFBP-6 may function as an antiproliferative molecule suppressing mitogenic effects of IGFs on Malassez cells.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/metabolism , Insulin-Like Growth Factor II/metabolism , Periodontal Ligament/metabolism , Tooth, Deciduous/metabolism , Cell Division , Child , Child, Preschool , Epithelial Cells/metabolism , Epithelial Cells/ultrastructure , Humans , Immunohistochemistry , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor II/analysis , Microscopy, Electron , Periodontal Ligament/cytology , Tooth, Deciduous/cytology
11.
Am J Physiol Gastrointest Liver Physiol ; 281(6): G1378-84, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11705742

ABSTRACT

In contrast to the adult gut, the immature intestine is refractory to subcutaneously infused insulin-like growth factor I (IGF-I). IGF binding protein (IGFBP) mRNA expression was characterized in intestinal tissues from 6-, 19-, and 90-day-old rats to determine if changes in local expression could account for this age-related change in IGF-I potency. For all age groups, IGFBP-3 to -6, but not IGFBP-1 or -2, were detected by Northern blot analysis. IGFBP-3, -4, and -5 were more intensely expressed in the 6-day-old rat intestine compared with weanling or adult tissue. In contrast, IGFBP-6 expression peaked at the time of weaning. In situ hybridization showed IGFBP-3 to -6 expression was confined to cells of the lamina propria and submucosa and also in the muscularis layer for IGFBP-5. Furthermore, the pattern of IGFBP-5 localization in the intestine changed with development. The findings indicate that the expression of IGFBP-3 to -6 is higher in the immature intestine compared with the adult intestine, suggesting locally produced IGFBPs may inhibit systemically derived IGF-I action in the intestine. Therefore, changes to local IGFBP expression may contribute to the varying response of the rat intestine to IGF-I peptides during postnatal development.


Subject(s)
Gene Expression , Insulin-Like Growth Factor Binding Proteins/genetics , Intestine, Small/growth & development , Aging , Animals , Blotting, Northern , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Female , In Situ Hybridization , Insulin-Like Growth Factor Binding Protein 1/analysis , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor Binding Proteins/blood , Intestine, Small/chemistry , Male , RNA, Messenger/analysis , Rats , Rats, Wistar
12.
Mund Kiefer Gesichtschir ; 5(4): 251-7, 2001 Jul.
Article in German | MEDLINE | ID: mdl-11550609

ABSTRACT

BACKGROUND: The insulin-like growth factor (IGF) system is an important regulator of cell growth and differentiation. The mitogenic and metabolic activities of IGFs are modulated by a family of six high-affinity IFG binding proteins (IGFBPs). IGFBP-6 is unique among the IGFBPs in its preferential binding of IGF II. METHODS: In this study, specific antibodies against recombinant mouse IGFBP-6 generated in chicken were used to localize IGFBP-6 by immunohistochemistry in the head region during late embryonic and newborn mice. RESULTS: Immunoreactivity was detected in oral and nasal mucosa, tooth-forming anlage, anlage of skeletal muscle, anlage of submandibular glands, enchondral ossification, and osteoclasts.


Subject(s)
Head/embryology , Insulin-Like Growth Factor Binding Protein 6/analysis , Animals , Animals, Newborn , Chickens , Cross Reactions , Female , Gestational Age , Humans , Mice , Pregnancy , Recombinant Proteins
13.
Endocrinology ; 140(12): 5944-52, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10579362

ABSTRACT

The insulin-like growth factor (IGF) system is an important regulator of fetal growth and differentiation. IGF bioavailability is modulated by IGF binding proteins (IGFBPs). We have generated six different antisera, directed to synthetic peptide fragments of mouse IGFBP-1 through -6. The specificity of the produced antisera was demonstrated by enzyme-linked immunosorbent assay, Western blotting, and by immunohistochemistry on sections of mouse embryos of 13.5 days post coitum. Specificity for the IGFBP-2 through -6 antisera also was confirmed immunohistochemically in liver and lung of corresponding gene deletion (knock-out) mutant mice and wild-type litter mates. Immunohistochemistry and messenger RNA (mRNA) in situ hybridization on sections of mouse embryos of 13.5 days post coitum revealed tissue-specific expression patterns for the six IGFBPs. The only site of IGFBP-1 protein and mRNA production was the liver. IGFBP-2, -4, and -5 protein and mRNA were detected in various organs and tissues. IGFBP-3 and -6 protein and mRNA levels were low. In several tissues, such as lung, liver, kidney, and tongue, more than one IGFBP (protein and mRNA) could be detected. Differences between mRNA and protein localization were extensive for IGFBP-3, -5, and -6, suggesting that these IGFBPs are secreted and transported. These results confirm the different spatial localization of the IGFBPs, on the mRNA and protein level. The overlapping mRNA and protein localization for IGFBP-2 and -4, on the other hand, may indicate that these IGFBPs also function in an auto- or paracrine manner.


Subject(s)
Embryo, Mammalian/chemistry , Immune Sera/biosynthesis , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor Binding Proteins/genetics , RNA, Messenger/analysis , Amino Acid Sequence , Animals , Antibody Specificity , Immunohistochemistry , Insulin-Like Growth Factor Binding Protein 1/analysis , Insulin-Like Growth Factor Binding Protein 1/chemistry , Insulin-Like Growth Factor Binding Protein 1/immunology , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/chemistry , Insulin-Like Growth Factor Binding Protein 2/immunology , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/chemistry , Insulin-Like Growth Factor Binding Protein 3/immunology , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/immunology , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Protein 5/immunology , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/chemistry , Insulin-Like Growth Factor Binding Protein 6/immunology , Insulin-Like Growth Factor Binding Proteins/immunology , Leukemia, Erythroblastic, Acute , Mice , Molecular Sequence Data , Tumor Cells, Cultured
14.
Horm Metab Res ; 31(2-3): 235-41, 1999.
Article in English | MEDLINE | ID: mdl-10226807

ABSTRACT

The Type-2 insulin-like growth factor receptor (IGF2R) mediates the transport of lysosomal hydrolases to lysosomes and the clearance of insulin-like growth factor II (IGF-II). Mutant mice lacking IGF2R usually die perinatally, but are completely rescued from lethality in the absence of IGF-II. IGF2R/IGF-II-deficient mice have elevated levels of circulating IGF binding protein (IGFBP)-3 and show a strong IGFBP-6 immunoreactivity in all pancreatic islet cells and in secretory granules of different size in acinar cells and interlobular connective tissue of exocrine pancreas. Fibroblasts derived from double mutant mice missort the lysosomal protease cathepsin D, and are able to degrade endocytosed (125I)IGFBP-3 intracellularly, however, with lower efficiency than in control cells. These results show that the deficiency of IGF2R and IGF-II affects the expression and metabolism of IGFBPs in a tissue- and cell type-specific manner.


Subject(s)
Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor II/genetics , Pancreas/chemistry , Receptor, IGF Type 2/genetics , Animals , Antigens, CD/analysis , Blotting, Western , Cathepsin D/analysis , Cells, Cultured , Culture Media, Conditioned/pharmacology , Endocytosis/physiology , Female , Fibroblasts/chemistry , Fibroblasts/cytology , Fibroblasts/drug effects , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/immunology , Insulin-Like Growth Factor II/analysis , Insulin-Like Growth Factor II/immunology , Lysosomal Membrane Proteins , Male , Membrane Glycoproteins/analysis , Mice , Mice, Knockout , Pancreas/cytology , Precipitin Tests , Receptor, IGF Type 2/analysis , Receptor, IGF Type 2/immunology
15.
J Endocrinol ; 157(2): 327-36, 1998 May.
Article in English | MEDLINE | ID: mdl-9659296

ABSTRACT

IGF-I has been proposed as a key regulator of mammary epithelial cell (MEC) growth and differentiation. As IGF-I bioactivity is modulated by specific, high-affinity binding proteins (IGFBP), the forms of IGFBP that are secreted by the bovine MEC line, MAC-T, were identified. Media conditioned by MAC-T cells contained four forms of IGFBP that were identified, by western blotting with specific antibodies, as IGFBP-2, -3, -4 and -6. The amounts of IGFBP-3 in conditioned media were relatively low under basal conditions when analyzed by ligand blotting with 125I-IGF-II, but were increased dramatically relative to serum-free controls by exposure to IGF-I (100 ng/ml) or IGF-II (100 ng/ml) for 24 h. These increases in IGFBP-3 protein corresponded with dose-dependent increases in IGFBP-3 mRNA, with IGF-II eliciting a smaller response than was elicited by IGF-I at each concentration. Leu-IGF-I, which has reduced affinity for the IGF-I receptor but normal affinity for IGFBPs, failed to increase IGFBP-3 protein and mRNA levels, whereas B-chain IGF-I (normal affinity for the receptor but reduced affinity for IGFBPs) elicited the response, thus implying an IGF-I receptor-mediated event. Time-course studies indicated that IGFBP-3 mRNA was increased fourfold by 3 h of IGF-I treatment, with maximal increases of eightfold above serum-free controls observed between 8 and 13 h of treatment. By 24 h of treatment, IGFBP-3 mRNA levels had declined and were approximately threefold above controls in cells exposed to IGF-I. Amounts of messenger RNA of IGFBP-6 and IGFBP-2 were not increased by IGF treatment. However, retinoic acid (10(-6) M) stimulated both IGFBP-2 and IGFBP-6 protein and mRNA levels, but it decreased IGFBP-3 mRNA levels relative to controls. The combination of retinoic acid plus IGF-I had no additional effect on IGFBP-6 or -2 above that observed with retinoic acid alone, whereas IGF-I together with retinoic acid attenuated the decrease in IGFBP-3 observed with retinoic acid alone. Protein kinase A-mediated pathways were also shown to alter IGFBP synthesis. Forskolin, which increases cAMP, increased IGFBP-3 protein and mRNA levels. The combination of IGF-I plus forskolin resulted in greater increases in both protein and mRNA than were observed with either treatment alone. In contrast, forskolin decreased IGFBP-6 mRNA relative to controls, but had no effect on IGFBP-2. The decrease in IGFBP-6 was less marked when cells were treated with a combination of IGF-I and forskolin. Forskolin had no effect on IGFBP-2 mRNA levels. In summary, the ability of IGF-I specifically to regulate IGFBP-3 synthesis represents a mechanism whereby IGF-I may regulate its own bioactivity. In addition, the differential regulation of IGFBP-2, -3 and -6 by retinoic acid (which inhibits proliferation) and IGF-I (which stimulates proliferation) suggests that these forms of IGFBP have different roles in regulating mammary epithelial cell physiology.


Subject(s)
Insulin-Like Growth Factor Binding Proteins/biosynthesis , Insulin-Like Growth Factor I/pharmacology , Mammary Glands, Animal/metabolism , Animals , Blotting, Northern , Blotting, Western , Cattle , Cell Line , Colforsin/pharmacology , Cyclic AMP/metabolism , Epithelium/drug effects , Epithelium/metabolism , Female , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor I/metabolism , Mammary Glands, Animal/drug effects , Polymerase Chain Reaction , RNA, Messenger/analysis , Tretinoin/pharmacology
16.
Endocrinology ; 138(10): 4181-90, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9322928

ABSTRACT

Previous studies have shown that osteogenic protein-1 (OP-1; also known as BMP-7) alters the steady state levels of messenger RNA (mRNA) encoding insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding proteins (IGFBPs) in primary cultures of fetal rat calvaria (FRC) cells. In the present study, the effects of exogenous IGF-I on bone cell differentiation and mineralized bone nodule formation induced by OP-1 were examined. Exogenous IGF-I synergistically and dose dependently enhanced OP-1 action in stimulating [3H]thymidine incorporation, alkaline phosphatase activity, PTH-dependent cAMP level, and bone nodule formation. Maximal synergism between OP-1 and IGF-I was observed when both factors were added simultaneously. Synergism was not observed when FRC cells were pretreated with IGF-I for 24 h, followed by OP-1 treatment. These findings suggest that IGF-I acted on OP-1-sensitized FRC cells. To examine the mechanism(s) by which this sensitization may occur, levels of mRNA encoding OP-1 receptor, IGF-I receptor, and IGFBPs were measured. The mRNA levels of both type I and II OP-1 receptors were elevated by OP-1, but were not changed further by combined OP-1 and IGF-I treatment. IGF-I receptor gene expression was not changed by OP-1, IGF-I, or a combination of both factors. OP-1 alone or together with IGF-I increased the steady state IGFBP-3 mRNA level and reduced the steady state mRNA levels of IGFBP-4, -5, and -6. IGF-I alone did not change the steady state mRNA levels of IGFBP-3, -4, and -6, but elevated that of IGFBP-5. Des(1-3)-IGF-I, which has a lower affinity for IGFBPs, was more effective than the full-length IGF-I in enhancing the OP-1-induced alkaline phosphatase activity. Exogenous IGFBP-5 inhibited the OP-1-induced alkaline phosphatase activity and reduced the synergistic stimulatory effect of IGF-I and OP-1. These findings strongly suggest that the OP-1-induced down-regulation of IGFBPs, especially that of IGFBP-5, is an important mechanism by which OP-1 and IGF-I synergize to stimulate FRC cell differentiation.


Subject(s)
Bone Morphogenetic Proteins/pharmacology , Insulin-Like Growth Factor I/pharmacology , Osteoblasts/cytology , Alkaline Phosphatase/analysis , Alkaline Phosphatase/metabolism , Animals , Base Sequence , Blotting, Northern , Bone Morphogenetic Protein 7 , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Line , Cyclic AMP/analysis , Cyclic AMP/metabolism , DNA, Complementary/analysis , DNA, Complementary/chemistry , DNA, Complementary/genetics , Dose-Response Relationship, Drug , Drug Interactions , Gene Expression Regulation , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 5/metabolism , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , RNA, Messenger/analysis , RNA, Messenger/chemistry , RNA, Messenger/genetics , Rats , Receptor, IGF Type 1/analysis , Receptor, IGF Type 1/genetics , Receptor, IGF Type 1/metabolism , Skull/cytology , Skull/embryology , Thymidine/metabolism , Transforming Growth Factor beta/pharmacology
17.
J Clin Endocrinol Metab ; 81(10): 3783-92, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8855838

ABSTRACT

Insulin-like growth factor (IGF)-binding proteins (IGFBPs) modulate the actions of IGF. We have previously reported that IGFBP-2 messenger ribonucleic acid (mRNA) and protein are increased, and IGFBP-3 protein decreased in malignant prostate epithelium compared to benign epithelium. In this study, we examined the other IGFBPs secreted by prostate cells in vitro, namely IGFBP-4, -5, and 6. Immunoreactivity and mRNA signals for IGFBP-4 and -6 were localized to epithelial cells, with less signal in stroma. IGFBP-4 immunostaining and hybridization signal were significantly increased in prostate adenocarcinoma compared to those in benign epithelium. Immunostaining for IGFBP-5 was localized to the epithelium and stroma. IGFBP-5 immunoreactivity was significantly increased in malignant compared to benign epithelium. IGFBP-5 mRNA signal was not localized to epithelial cells; rather, the signal was over stromal cells surrounding the acinar structures. These cells are thought to be fibroblasts. We show that IGFBP-4 mRNA and protein and IGFBP-5 protein are increased in malignant epithelium compared to benign epithelium, that IGFBP-6 is present in benign and malignant epithelium, and that there is differential localization of IGFBP-5 mRNA and protein in prostate tissue. IGFBP-5 that is made by fibroblasts appears to be sequestered by epithelial cells. IGFBP-5 may, therefore, be a factor in cellular interactions between stromal and epithelial cells that are of fundamental importance for normal prostatic development and function.


Subject(s)
Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 6/analysis , Prostate/chemistry , Prostatic Neoplasms/chemistry , RNA, Messenger/analysis , Aged , Epithelium/chemistry , Humans , Immunohistochemistry , In Situ Hybridization , Insulin-Like Growth Factor Binding Protein 5/genetics , Keratins/analysis , Male , Middle Aged
18.
Biol Reprod ; 55(4): 803-12, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8879493

ABSTRACT

Estradiol (E2)-active (Day 5 [D5]), transitional E2-active (D8), atretic (D12 - 1), and E2-sustained dominant follicles (DF, D12 + 1) and associated subordinate follicles (SF) were obtained through use of an experimental model described here. The ovary bearing the DF was surgically removed by colpotomy, and individual follicles were utilized to study changes in concentrations of insulin like growth factor-I (IGF-I) and -II (IGF-II) and changes in amounts and proportions of the different IGF-binding proteins (IGFBP) present in follicular fluid (FF). The ratio of FF E2 to progesterone (EPR) was utilized to classify follicles into E2 active (EPR > 1) and E2 inactive (EPR < 1). The IGF-I and IGF-II concentrations in FF were similar among experimental groups and between DF and SF. Six different molecular mass bands (49, 43, 35, 30, 28, and 22 kDa) were detected by ligand blot in FF of DF and SF. Immunoprecipitation analysis identified four IGFBPs (-2, -3, -4, and -5) in FF. The 35-kDa band corresponded to IGFBP-2, the 49- and 43-kDa bands to IGFBP-3, the 28- and 22-kDa bands to IGFBP-4, and the 30-kDa band to IGFBP-5. No IGFBP-6 was found by immunoprecipitation. Absolute amounts and proportions of low molecular mass IGFBPs (-2, -4, and -5) were increased with atresia of the DF and in SF compared to E2-active DF. Conversely, although absolute amounts of IGFBP-3 remained unchanged, their proportion in FF decreased in SF compared to DF. The ratio of IGF-I to IGFBPs decreased with atresia of the DF, possibly leaving less bioavailable IGF-I to increase FSH action at the level of the follicle.


Subject(s)
Follicular Fluid/chemistry , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor II/analysis , Insulin-Like Growth Factor I/analysis , Ovarian Follicle/physiology , Animals , Cattle , Cohort Studies , Electrophoresis, Polyacrylamide Gel , Estradiol/analysis , Female , Immune Sera/immunology , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/immunology , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/immunology , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/immunology , Insulin-Like Growth Factor Binding Protein 5/analysis , Insulin-Like Growth Factor Binding Protein 5/immunology , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/immunology , Ligands , Precipitin Tests , Progesterone/analysis , Radioimmunoassay , Random Allocation , Regression Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...